Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.
Atyr Pharma Inc (NASDAQ: ATYR) closed the day trading at $0.73 down -2.87% from the previous closing price of $0.75. In other words, the price has decreased by -$2.87 from its previous closing price. On the day, 1.35 million shares were traded. ATYR stock price reached its highest trading level at $0.7449 during the session, while it also had its lowest trading level at $0.7176.
Ratios:
For a better understanding of ATYR, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.93 and its Current Ratio is at 5.93. In the meantime, Its Debt-to-Equity ratio is 0.15 whereas as Long-Term Debt/Eq ratio is at 0.14.
On September 15, 2025, Wells Fargo Downgraded its rating to Equal Weight which previously was Overweight but kept the price unchanged to $1.
Leerink Partners Downgraded its Outperform to Market Perform on September 15, 2025, while the target price for the stock was maintained at $1.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Oct 08 ’25 when SCHIMMEL PAUL bought 682,001 shares for $0.90 per share. The transaction valued at 612,437 led to the insider holds 1,095,024 shares of the business.
SCHIMMEL PAUL bought 317,999 shares of ATYR for $299,364 on Oct 09 ’25. The Director now owns 1,413,023 shares after completing the transaction at $0.94 per share. On Mar 17 ’25, another insider, Gross Jane A, who serves as the Director of the company, bought 3,750 shares for $4.00 each. As a result, the insider paid 15,000 and bolstered with 9,750 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ATYR now has a Market Capitalization of 71050104 and an Enterprise Value of -6983891. For the stock, the TTM Price-to-Sale (P/S) ratio is 373.96 while its Price-to-Book (P/B) ratio in mrq is 0.89. Its current Enterprise Value per Revenue stands at -36.757 whereas that against EBITDA is 0.09.
Stock Price History:
The Beta on a monthly basis for ATYR is 0.60, which has changed by -0.7883853 over the last 52 weeks, in comparison to a change of 0.1877265 over the same period for the S&P500. Over the past 52 weeks, ATYR has reached a high of $7.29, while it has fallen to a 52-week low of $0.64. The 50-Day Moving Average of the stock is -5.59%, while the 200-Day Moving Average is calculated to be -76.08%.
Shares Statistics:
Over the past 3-months, ATYR traded about 3.98M shares per day on average, while over the past 10 days, ATYR traded about 1834470 shares per day. A total of 97.99M shares are outstanding, with a floating share count of 95.56M. Insiders hold about 2.48% of the company’s shares, while institutions hold 63.38% stake in the company. Shares short for ATYR as of 1765756800 were 30385566 with a Short Ratio of 7.63, compared to 1763078400 on 29864642. Therefore, it implies a Short% of Shares Outstanding of 30385566 and a Short% of Float of 37.09.
Earnings Estimates
The stock of Atyr Pharma Inc (ATYR) is currently drawing attention from 8.0 analysts actively involved in the ongoing evaluation and rating process.The consensus estimate for the next quarter is -$0.15, with high estimates of -$0.12 and low estimates of -$0.18.
Analysts are recommending an EPS of between -$0.77 and -$0.87 for the fiscal current year, implying an average EPS of -$0.82. EPS for the following year is -$0.56, with 10.0 analysts recommending between -$0.22 and -$0.82.
